Story

Novo Nordisk Downgraded to Sell by Deutsche Bank on Growth Concerns

ENTHMSVIIDZHZH-TWJAKOHI
Aug 27, 20262 min read
Novo Nordisk Downgraded to Sell by Deutsche Bank on Growth Concerns
Text size
Background

Deutsche Bank has downgraded Novo Nordisk (NYSE: NVO) to Sell from Hold, citing persistent concerns about the company's future growth prospects. The ratings cut prompted a more than 3% decline in the company's shares during Copenhagen trading on Thursday.

Analyst Cites Long-Term Risks

In a note to clients, Deutsche Bank analyst Emmanuel Papadakis announced the downgrade and a 9% reduction in the price target for Novo Nordisk's stock, lowering it to 265 Danish crowns from a previous 290 crowns. The decision follows the company's "mixed" second-quarter earnings report, recent meetings with the firm, and an analysis of prescription trends.

This marks the second time Deutsche Bank has lowered its rating on the drugmaker this year. The bank previously cut its recommendation to Hold in February.

Rationale Behind the Downgrade

The analyst report pointed to several factors weighing on the company's outlook, contributing to what the bank described as "high-single-digit mid-term revenue cuts." Key concerns include:

Sample IUX Markets – In-articleAd
  • A narrow sales miss for the new Wegovy pill, which reported sales of 3.22 billion Danish crowns ($497 million), just below the analyst consensus of 3.3 billion crowns.
  • A recent trial setback for its next-generation obesity drug, CagriSema.
  • The view that another drug, ziltivekimab, is now "effectively out of the picture."
  • Concerns about the company's ability to return to growth in 2027 and a potential "large cliff problem further out."

Market Context and Outlook

The downgrade comes despite Novo Nordisk raising its full-year profit and sales outlook earlier this month. The company now expects both metrics to fall in a range of 0% to -6% at constant exchange rates, an improvement from its prior forecast of -12% to -4%.

However, investors appear to be focused on longer-term challenges as Novo Nordisk competes with rival Eli Lilly for dominance in the lucrative obesity drug market. Deutsche Bank noted that "information uncertainty remains high" ahead of the company's Capital Markets Day, which is scheduled for September 21.

Read next

More on Stocks
Back to latest news

LATEST